Clinical Evaluation of Drug–Drug Interactions in Hospitalized Patients with Cardiovascular Disorders
Downloads
Drug–drug interactions (DDIs) represent a significant clinical challenge in the management of patients with cardiovascular disorders, especially during hospitalization when multiple medications are administered concurrently. This study aims to evaluate the prevalence, types, and clinical significance of DDIs among hospitalized cardiovascular patients, identifying risk factors and proposing strategies for prevention and management. A prospective observational study was conducted on 250 patients admitted for cardiovascular conditions including hypertension, ischemic heart disease, and heart failure. Using drug interaction databases and clinical assessment tools, potential and actual DDIs were identified and classified. Results revealed that 68% of patients experienced at least one potential DDI, with 21% experiencing clinically significant interactions leading to adverse events or therapy modification. Polypharmacy, older age, and renal impairment were major risk factors. Implementation of clinical pharmacology services and computerized alert systems are recommended to minimize DDI-related complications and improve patient outcomes.
1. Gandhi TK, Weingart SN, Borus J, et al. Adverse drug events in ambulatory care. N Engl J Med. 2003;348(16):1556–1564.
2. Figueiras A, Caamaño F, Gestal-Otero JJ. Influence of patients’ age on adverse drug reactions: a prospective study. Drug Saf. 2002;25(7):545–554.
3. Juurlink DN, Mamdani MM, Kopp A, et al. Drug–drug interactions among elderly patients hospitalized for drug toxicity. JAMA. 2003;289(13):1652–1658.
4. Raskin M, Kozer E, Nulman I, et al. Predictors of drug interactions in hospitalized patients. Clin Pharmacol Ther. 2006;80(3):248–257.
5. Zecconi A, Zuccari G. Drug–drug interactions and the hospitalized elderly patient. Drug Saf. 2004;27(14):1165–1175.
6. Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18,820 patients. BMJ. 2004;329(7456):15–19.
7. Tahaineh LM, Albsoul-Younes AM, Al-Sheikh AY, et al. Potential drug–drug interactions among hospitalized cardiac patients in Jordan. Pharmacoepidemiol Drug Saf. 2011;20(4):423–429.
8. Kaur S, Singh H, Singh S. Evaluation of drug–drug interactions in cardiovascular patients admitted to intensive care units. Int J Clin Pharm. 2017;39(2):344–350.
